Journal of Clinical Oncology, Vol 16, 1519-1525, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Competitive CBFbeta/MYH11 reverse-transcriptase polymerase chain reaction for quantitative assessment of minimal residual disease during postremission therapy in acute myeloid leukemia with inversion(16): a pilot study

K Laczika, M Novak, B Hilgarth, M Mitterbauer, G Mitterbauer, A Scheidel- Petrovic, C Scholten, R Thalhammer-Scherrer, S Brugger, F Keil, I Schwarzinger, OA Haas, K Lechner and U Jaeger
Department of Medicine I, Clinical Institute of Medical and Chemical Laboratory Diagnosis, University of Vienna, St Anna Children's Hospital, Austria.

PURPOSE: (1) Quantification of minimal residual disease (MRD) by competitive CBFbeta/MYH11 reverse-transcriptase polymerase chain reaction (RT-PCR) in patients with acute myeloid leukemia (AML) and inversion(16) [inv(16)] during postremission therapy, (2) comparison of this method with conventional two-step RT-PCR, and (3) evaluation of a potential prognostic value. PATIENTS AND METHODS: MRD of six consecutive adult patients with AML and inv(16)(p13;q22) or t(16;16)(p13;q22) who entered complete remission (CR) was monitored by competitive CBFbeta/MYH11 RT-PCR in their bone marrow (BM) during postremission therapy with high-dose cytarabine (HiDAC) or after BM transplantation with a matched unrelated-donor marrow (MUD-BMT) during an observation period of 4.5 to 27 months after initiation of treatment. RESULTS: Competitive PCR showed a gradual decline by at least 4 orders of magnitude after 7 to 9 months in patients in continuous CR (CCR), while one patient who relapsed after 13.5 months only achieved a reduction by 2 orders of magnitude at the end of consolidation therapy. A rapid decrease below the detection limit was observed within 1 month in two patients after MUD-BMT. A temporary reappearance of molecular MRD was observed in these patients during immunosuppression for graft-versus-host disease (GvHD). After reduction of immunosuppression, the level of MRD dropped again below the PCR detection limit. Molecular monitoring by conventional two-step RT-PCR yielded comparable results only when multiple assays per time point were performed, while single-assay RT-PCR gave misleading results. CONCLUSION: Competitive RT-PCR is a valuable tool for molecular monitoring during postremission chemotherapy, as well as after BMT.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				W. R. Sperr, M. Mitterbauer, G. Mitterbauer, M. Kundi, U. Jager, K. Lechner, and P. Valent Quantitation of Minimal Residual Disease in Acute Myeloid Leukemia by Tryptase Monitoring Identifies a Group of Patients with a High Risk of Relapse Clin. Cancer Res., September 15, 2005; 11(18): 6536 - 6543. [Abstract] [Full Text] [PDF]

				J. Krauter, K. Gorlich, O. Ottmann, M. Lubbert, H. Dohner, W. Heit, L. Kanz, A. Ganser, and G. Heil Prognostic Value of Minimal Residual Disease Quantification by Real-Time Reverse Transcriptase Polymerase Chain Reaction in Patients With Core Binding Factor Leukemias J. Clin. Oncol., December 1, 2003; 21(23): 4413 - 4422. [Abstract] [Full Text] [PDF]

				P. D. Kottaridis, R. E. Gale, S. E. Langabeer, M. E. Frew, D. T. Bowen, and D. C. Linch Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors Blood, September 18, 2002; 100(7): 2393 - 2398. [Abstract] [Full Text] [PDF]

				W. R. Sperr, J.-H. Jordan, M. Baghestanian, H.-P. Kiener, P. Samorapoompichit, H. Semper, A. Hauswirth, G.-H. Schernthaner, A. Chott, S. Natter, et al. Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia Blood, October 1, 2001; 98(7): 2200 - 2209. [Abstract] [Full Text] [PDF]